<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Venous <z:hpo ids='HP_0001907'>thromboembolic disease</z:hpo> is a major cause of morbidity and mortality, necessitating antithrombotic therapy </plain></SENT>
<SENT sid="1" pm="."><plain>A human monoclonal anti-factor (F)VIII antibody, LCL-mAb-LE2E9, produced by a lymphoblastoid cell line derived from a <z:e sem="disease" ids="C0684275,C0019069" disease_type="Disease or Syndrome" abbrv="">hemophilia</z:e> A patient with inhibitor to <z:mp ids='MP_0002169'>wild-type</z:mp> but not mutant self FVIII, was previously reported to achieve efficient inhibition of <z:mp ids='MP_0005048'>thrombosis</z:mp> in an experimental vena cava <z:mp ids='MP_0005048'>thrombosis</z:mp> model in mice </plain></SENT>
<SENT sid="2" pm="."><plain>Here, the antithrombotic efficacy of a recombinant DNA-derived version of this anti-FVIII antibody (rec-mAb-LE2E9) was tested in mice which carry a type II <z:chebi fb="5" ids="28304">heparin</z:chebi> binding site <z:e sem="disease" ids="C0272375" disease_type="Disease or Syndrome" abbrv="">antithrombin deficiency</z:e> mutation and display spontaneous <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0005048'>thrombosis</z:mp> in several sites including the penile vein of sexually active males </plain></SENT>
<SENT sid="3" pm="."><plain>The recombinant anti-FVIII antibody (100 microg, repeated after 3 days) prevented thrombotic <z:hpo ids='HP_0200023'>priapism</z:hpo> in <z:hpo ids='HP_0000001'>all</z:hpo> treated males, whereas <z:hpo ids='HP_0000001'>all</z:hpo> control animals treated with saline (group of four animals) developed <z:hpo ids='HP_0200023'>priapism</z:hpo> within 6 days after mating (P &lt; 0.05 for treated vs. saline) </plain></SENT>
<SENT sid="4" pm="."><plain>The rec-mAb-LE2E9 and the original LCL-mAb-LE2E9 were equally effective (five and seven males/group, respectively) </plain></SENT>
<SENT sid="5" pm="."><plain>These results confirm that FVIII inhibition represents a potent antithrombotic strategy, and show that both LCL-mAb-LE2E9 and rec-mAb-LE2E9 efficiently prevent <z:mp ids='MP_0005048'>thrombosis</z:mp> in a physiological model representative of <z:mp ids='MP_0005048'>thrombosis</z:mp> in patients with a severe prothrombotic risk </plain></SENT>
</text></document>